Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis.

ABSTRACT:

Introduction

Various insulin therapies for Diabetes Mellitus offer different benefits while having potential risks. We aim to compare Insulin Icodec, a novel Insulin analogue with the ease of once-weekly administration, to the once-daily Insulin Glargine U100 regarding glycemic control and safety profile.

Methods

We performed a systematic literature search of electronic databases for peer-reviewed articles from inception until September 1 2023.

Results

A total of 2215 type 2 diabetic patients were included, of which 1209 received Insulin Icodec and1048 recieved Insulin Glargine U100. In terms of glycemic control, Insulin Icodec showed a significantly longer time in the target glucose range (MD: 0.304, CI: 0.069, P = 0.000) and a more significant reduction in Hb

SUBMITTER: Zuhair V 

PROVIDER: S-EPMC11196528 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature